Sep 25, 2026.
The IN-ARMOR consortium has reached a further milestone in the development of innovative delivery systems for its host-directed therapies against antimicrobial resistance (AMR).
As part of Work Package 3 (WP3), led by CINBIO – University of Vigo, researchers have successfully completed the optimisation and comprehensive characterisation of the project’s mesoporous silica nanoparticle (MSNP)-based nanocarriers.
These nanostructures are being developed to address one of the key challenges in oral delivery: protecting therapeutic compounds as they pass through the gastrointestinal environment and enabling their controlled delivery where they are needed.
The project team has carried out a comprehensive physicochemical characterisation of the nanocarriers, examining properties that are essential for their future application, including their size, pore structure, surface characteristics and stability.
Developing a targeted delivery approach
The optimisation of these nanocarriers is an important step in the IN-ARMOR strategy. By using engineered nanoscale delivery systems, the project aims to improve the protection and delivery of its therapeutic candidates while supporting their activity in the intestinal environment.
The work carried out in WP3 is closely connected with the activities of the other scientific work packages. The nanocarriers will provide a delivery platform for the compounds selected and characterised through the project’s earlier research activities, supporting their progression towards preclinical evaluation.
The successful completion of this milestone therefore strengthens the integration of drug discovery, biological validation and nanotechnology within the IN-ARMOR pipeline.
